Sera Prognostics (NASDAQ:SERA – Get Rating) will post its quarterly earnings results after the market closes on Tuesday, May 10th. Analysts expect Sera Prognostics to post earnings of ($0.34) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.
Sera Prognostics (NASDAQ:SERA – Get Rating) last posted its quarterly earnings results on Tuesday, March 29th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.29) by ($0.12). On average, analysts expect Sera Prognostics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Shares of SERA stock traded down $0.04 during midday trading on Tuesday, reaching $2.21. 4 shares of the company traded hands, compared to its average volume of 86,653. The business’s 50 day moving average price is $3.44. Sera Prognostics has a 1-year low of $1.98 and a 1-year high of $15.50.
Several institutional investors and hedge funds have recently modified their holdings of SERA. Bank of America Corp DE increased its stake in shares of Sera Prognostics by 768.8% during the 4th quarter. Bank of America Corp DE now owns 3,597 shares of the company’s stock worth $25,000 after purchasing an additional 3,183 shares in the last quarter. American International Group Inc. purchased a new position in shares of Sera Prognostics during the 3rd quarter worth approximately $29,000. Norges Bank purchased a new position in shares of Sera Prognostics during the 4th quarter worth approximately $255,000. State Street Corp increased its stake in shares of Sera Prognostics by 33.3% during the 4th quarter. State Street Corp now owns 40,801 shares of the company’s stock worth $280,000 after purchasing an additional 10,201 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Sera Prognostics by 17.8% during the 4th quarter. Geode Capital Management LLC now owns 61,231 shares of the company’s stock worth $420,000 after purchasing an additional 9,262 shares in the last quarter. 63.20% of the stock is owned by institutional investors and hedge funds.
About Sera Prognostics (Get Rating)
Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies.
- Get a free copy of the StockNews.com research report on Sera Prognostics (SERA)
- Another Buy The Dip Opportunity In Freshpet
- Inflation Wreaks Havoc On Haverty Furniture Company
- Tractor Supply Stock Should Plow Ahead
- MarketBeat Podcast: Investing In Innovation, Robotics, AI and Healthcare
- Saia Growth Accelerates But It May Not Matter
Receive News & Ratings for Sera Prognostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sera Prognostics and related companies with MarketBeat.com's FREE daily email newsletter.